Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
ACADIA Pharmaceuticals (Nasdaq: ACAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. We currently have five programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs and major commercial markets. Our four Phase II-stage clinical programs, for which we have retained worldwide commercialization rights, are ACP-103 for treatment-induced dysfunctions in Parkinson’s disease, ACP-103 as an adjunctive therapy for schizophrenia, ACP-103 for treatment of sleep maintenance insomnia, and ACP-104 for treatment of ( www.acadia-pharm.com )
ACADIA Pharmaceuticals Inc.
3911 Sorrento Valley Blvd.
San Diego, California 92121
USA
Tel: (858) 558-2871
Fax: (858) 558-2872